Multiple Sclerosis and Autologous Stem Cell Transplantation

Multiple Sclerosis and Autologous Stem Cell Transplantation

Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder characterised by inflammation, demyelination, and neurodegeneration within the central nervous system (CNS). It leads to progressive disability, including motor dysfunction, sensory disturbances, and cognitive decline. Although several disease-modifying therapies (DMTs) are available, some patients experience aggressive disease that is refractory to conventional treatments. For these patients, autologous haematopoietic stem cell transplantation (AHSCT) has emerged as a promising therapeutic approach to reset the immune system and halt disease progression. https://bmtnext.com/

What is Autologous Stem Cell Transplantation?

AHSCT involves harvesting haematopoietic stem cells from the patients own bone marrow or peripheral blood, followed by administration of high-dose chemotherapy to ablate the diseased immune system. The collected stem cells are then reinfused to restore immune function. This process aims to reboot the immune system, eliminating autoreactive immune cells that attack myelin and neurones.

Rationale for AHSCT in MS

• MS is driven by autoreactive lymphocytes that cross the blood-brain barrier and attack CNS myelin.

• Traditional DMTs suppress immune activity but may fail in aggressive or rapidly progressive MS.

• AHSCT provides a more intensive approach, eradicating these autoreactive immune cells and allowing regeneration of a more tolerant immune system.

• Early studies and clinical trials have demonstrated durable remission and improved neurological outcomes post-transplant.

Who is a candidate for AHSCT?

• Patients with relapsing-remitting MS (RRMS) who have active disease despite treatment with at least one high-efficacy DMT.

• Selected patients with secondary progressive MS (SPMS) with ongoing inflammatory activity.

• Generally younger patients with less disability (e.g., Expanded Disability Status Scale [EDSS] score less than 6).

• Patients without significant comorbidities that would increase transplant risk.

Procedure Overview

1. Mobilisation and Harvesting: Patients receive growth factors (e.g., G-CSF) to mobilise stem cells into the peripheral blood, which are then collected via apheresis.

2. Conditioning Regimen: High-dose chemotherapy (e.g., the BEAM regimencarmustine, etoposide, cytarabine, melphalan) or other immunoablative protocols are used to eradicate autoreactive immune cells.

3. Stem Cell Infusion: The collected autologous stem cells are reinfused to restore haematopoiesis.

4. Recovery: Patients are monitored for engraftment, infections, and complications. Immune system reconstitution takes several months.

Efficacy and Outcomes

• Several phase II and observational studies have shown that AHSCT can lead to:

  • Significant reduction in relapse rates.

  • Stabilisation or improvement in disability scores.

  • MRI evidence of reduced or no new lesions.

• Long-term follow-up studies demonstrate durable remission lasting years.

• Compared to traditional DMTs, AHSCT may offer better disease control in highly active MS.

Risks and Complications

• Treatment-related mortality is low but not negligible (~1-2% in experienced centres).

• Risks include infections due to immune ablation, organ toxicity, and infertility.

• Graft failure is rare since it is an autologous transplant.

• Careful patient selection and centre experience are critical to minimising risks.

Current Guidelines and Research

• Professional societies like the American Society for Blood and Marrow Transplantation (ASBMT) and the European Society for Blood and Marrow Transplantation (EBMT) provide guidelines for patient selection.

• Ongoing randomised controlled trials (RCTs) are comparing AHSCT to the best available therapies.

• Research is focused on optimising conditioning regimens to balance efficacy and safety.

Conclusion

Autologous haematopoietic stem cell transplantation is a transformative treatment option for patients with aggressive, treatment-resistant multiple sclerosis. By effectively rebooting the immune system, AHSCT offers the potential for long-term remission and improved quality of life. While it carries risks inherent to transplantation, careful patient selection and advances in supportive care continue to improve outcomes. As research progresses, AHSCT is likely to become an increasingly important component of MS management in carefully selected patients. https://bmtnext.com/